Allogene's BCMA-Targeted Therapy Gets US Orphan Drug Tag For Multiple Myeloma

by Vandana Singh, Benzinga Editor

August 12, 2021 11:06 AM | 28 seconds read |

The FDA has granted Orphan Drug Designation to Allogene Therapeutics Inc's ALLO ALLO-715 to treat multiple myeloma.
In April 2021, ALLO-715 received Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA.
ALLO-715, an AlloCAR T therapy targeting B-cell maturation antigen (BCMA), is a potential novel treatment for multiple myeloma and other BCMA-positive malignancies.
Price Action: ALLO shares are down 2.35% at $20.75 during the market session on the last check Thursday.
Related content: Benzinga's Full FDA Calendar.

Posted In: Biotech News Health Care FDA General Briefs multiple myeloma Orphan Drug Designation

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.